Aurinia v. Lotus Pharmaceutical: LUPKYNIS Voclosporin Patent Dispute Consolidated
Aurinia Pharmaceuticals filed suit against Lotus Pharmaceutical in New Jersey District Court, asserting two patents covering voclosporin — the active ingredient in its branded LUPKYNIS® drug — against Lotus’s proposed generic. After 236 days, the case was consolidated into lead action No. 25-2580 for unified pre-trial proceedings.
Aurinia defends LUPKYNIS exclusivity against Lotus generic entry bid
On April 11, 2025, Aurinia Pharmaceuticals, Inc. filed this patent infringement action in the U.S. District Court for the District of New Jersey against Lotus Pharmaceutical Co., Ltd., a Taiwan-based generic drug manufacturer. The suit asserts two patents — US11622991B2 and US10286036B2 — covering voclosporin, the calcineurin inhibitor active ingredient in Aurinia’s branded LUPKYNIS® product, which is approved for lupus nephritis treatment. Lotus’s proposed generic product triggered the suit under the Hatch-Waxman framework.
On December 3, 2025, after 236 days, the Court entered a consolidation order under Federal Rule of Civil Procedure 42 and Local Civil Rule 42.1, merging this case with related action No. 25-2580, which was designated the Lead Case. The consolidation was unopposed by all parties and covers all pre-trial purposes including discovery and case management. This case (2:25-cv-02613) is now effectively subsumed into the lead docket, with all future filings directed to No. 25-2580.
The relatively swift consolidation — under eight months from filing — suggests Aurinia pursued coordinated litigation strategy against multiple generic filers simultaneously, consistent with standard Hatch-Waxman 30-month stay mechanics. The consolidation order itself reflects no merits ruling; the substantive question of whether Lotus’s generic infringes Aurinia’s voclosporin patents remains fully open. The public record of this docket is silent on any licensing discussions or settlement posture between the parties.
Filing to Case Consolidated in 236 days
236 days from filing to consolidation order — typical for ANDA patent cases consolidated at early pre-trial stage
What consolidation into lead case 25-2580 means for both parties
Consolidation under FRCP 42 — no merits ruling
The Court consolidated this action into lead case No. 25-2580 under Federal Rule of Civil Procedure 42(a), which permits consolidation of actions sharing common questions of law or fact. The order covers all pre-trial purposes including discovery and case management. Consolidation does not adjudicate infringement, validity, or any substantive patent issue — it is a procedural efficiency measure that centralises related Hatch-Waxman suits arising from Lotus’s ANDA filing.
Procedural — no merits decidedAurinia retains full enforcement posture under unified docket
Consolidation is broadly neutral-to-favourable for Aurinia. By coordinating discovery across related generic-challenger actions in a single proceeding, Aurinia can present a unified claim construction and infringement theory, reduce duplicative litigation costs, and protect the 30-month Hatch-Waxman stay period more efficiently. Aurinia’s two voclosporin patents remain in force and actively asserted; no adverse merits finding has been made.
Patents remain assertedLotus faces consolidated discovery alongside other generic filers
For Lotus, consolidation means its invalidity and non-infringement defences will be litigated in parallel with those of other generic challengers in the lead case. This can create strategic complexity — positions taken by one generic filer may affect or constrain others. However, consolidation also reduces per-party discovery burden and may accelerate a merits hearing. Lotus has not opposed consolidation, suggesting it may perceive tactical advantages in the combined proceeding.
Defences still to be arguedLUPKYNIS market exclusivity window remains contested
LUPKYNIS (voclosporin) holds FDA approval for lupus nephritis — a rare, high-value indication with limited therapeutic alternatives. Aurinia’s ability to maintain market exclusivity until patent expiry depends on the outcome of the consolidated Hatch-Waxman proceedings. The involvement of multiple generic filers (suggested by consolidation of multiple suits) signals a competitive generic entry race. The ultimate merits ruling in lead case 25-2580 will likely determine the market entry timeline for all challengers.
Exclusivity at stake in lead caseFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aurinia Pharmaceuticals, Inc. | Company | Specialty biopharma company — holder of US11622991B2 and US10286036B2 (LUPKYNIS/voclosporin)Search in Eureka ↗ |
| Defendant | Lotus Pharmaceutical Co., Ltd. | Company | Lotus Pharmaceutical Co., Ltd. — Taiwan-based generic drug manufacturer seeking ANDA approvalSearch in Eureka ↗ |
| Plaintiff counsel | C. COLLETTE CORSER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | DANIELLE A. DUSZCZYSZYN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMILY R. GABRANSKI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMMA CAPITANELLI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JUSTIN SILVERBERG | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MARK FELDSTEIN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | RYAN V. MCDONNELL | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for Lotus Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing Lotus Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is purely procedural: it reflects the Court’s finding of common questions of law and fact across related voclosporin ANDA suits, and the absence of any party opposition. The order makes no finding on infringement, invalidity, or enforceability of US11622991B2 or US10286036B2. Its practical effect is to direct all future filings to lead case 25-2580, meaning the substantive merits of Aurinia’s patent claims against Lotus will be resolved on that docket. No damages, injunction, or claim construction ruling has been entered.
US11622991B2 & US10286036B2 — voclosporin formulation and treatment patents
US11622991B2 and US10286036B2 are the two patents Aurinia is asserting in this Hatch-Waxman litigation. Both relate to voclosporin — a next-generation calcineurin inhibitor structurally distinct from cyclosporine, approved under the brand name LUPKYNIS for active lupus nephritis in adults. US10286036B2 is the earlier patent, filed under application No. US15/835219, while US11622991B2 is the later-issued patent filed under application No. US17/713140, suggesting layered portfolio protection covering the same drug across different claim aspects.
Voclosporin’s FDA approval for lupus nephritis — a serious autoimmune renal condition with few approved therapies — gives these patents significant commercial value. Aurinia’s enforcement strategy of asserting both patents against multiple generic filers simultaneously is consistent with the industry practice of building a ‘patent thicket’ around approved specialty drugs to maximise Hatch-Waxman exclusivity periods. Any company developing calcineurin inhibitor formulations, or targeting the lupus nephritis indication, should conduct thorough freedom-to-operate analysis against both patents before commencing clinical or regulatory activities.
Should you run an FTO analysis against US11622991B2 and US10286036B2?
Any pharmaceutical company, contract development organisation, or generic drug manufacturer working with voclosporin — or developing calcineurin inhibitor-based therapies for lupus nephritis or related autoimmune indications — should treat these two patents as live enforcement risks. Aurinia has demonstrated willingness to assert both patents simultaneously against ANDA filers. R&D teams developing novel formulations in this space should map their compositions against the independent claims of both patents before filing regulatory submissions.
PatSnap Eureka’s FTO Search Agent can rapidly analyse the claim scope of US11622991B2 and US10286036B2, identify prosecution history estoppel, and surface prior art combinations relevant to potential invalidity arguments. Eureka’s litigation monitoring module also tracks the lead case 25-2580 docket in real time, alerting your team to claim construction orders, expert disclosures, and any PTAB petitions filed against either patent — giving IP and R&D teams the earliest possible signal on exclusivity risk.
Run a freedom-to-operate analysis on US11622991B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman voclosporin and calcineurin inhibitor patent cases
Cases below involve Hatch-Waxman ANDA patent disputes in the D.N.J. over specialty biopharma formulations, calcineurin inhibitors, and lupus nephritis treatments.
What this case signals for the voclosporin and biopharma patent IP landscape
Multiple generic challengers targeting LUPKYNIS indicates Aurinia’s voclosporin franchise faces organised patent pressure ahead of potential exclusivity cliff.
Multi-filer ANDA litigation signals competitive generic interest in LUPKYNIS
The consolidation of at least two related patent suits against generic filers — with this case merged into lead action 25-2580 — is consistent with a wave of Paragraph IV ANDA filings targeting LUPKYNIS. Biopharma IP teams monitoring orphan or rare-disease drug exclusivity should track the lead case docket closely for claim construction orders and any 30-month stay expiry dates.
Consolidation does not alter Hatch-Waxman 30-month stay mechanics
Procedural consolidation under FRCP 42 does not reset or extend the 30-month stay triggered by Aurinia’s original patent infringement suit. Generic filers and market access teams should independently calculate stay expiry dates from the original ANDA notification dates, as the stay timeline runs per-filer — not per-case docket.
Aurinia v Lotus — key questions answered
The case was consolidated into lead action No. 25-2580 by order dated December 3, 2025. Aurinia filed a patent infringement suit against Lotus’s proposed generic voclosporin product, asserting US11622991B2 and US10286036B2. The consolidation order was procedural — no merits ruling on infringement or validity was made in this docket.
Aurinia asserted two patents: US11622991B2 (application No. US17/713140) and US10286036B2 (application No. US15/835219). Both patents relate to voclosporin, the calcineurin inhibitor active ingredient in LUPKYNIS, which is approved for lupus nephritis. Both patents remain asserted in the consolidated lead case 25-2580.
Consolidation under Federal Rule of Civil Procedure 42(a) merges two or more actions sharing common legal or factual questions into a single coordinated proceeding. Here, this case and at least one other related ANDA suit are now managed together under lead case 25-2580. There is no merits ruling; Aurinia’s patents remain asserted and Lotus’s defences remain fully open.
LUPKYNIS (voclosporin) is an FDA-approved calcineurin inhibitor for active lupus nephritis in adults. It is Aurinia’s primary commercial product. Generic drug manufacturers, including Lotus, have filed Abbreviated New Drug Applications (ANDAs) seeking to market generic versions before Aurinia’s patents expire, triggering Hatch-Waxman patent litigation to determine whether generic entry is permissible.
The consolidation order does not alter the 30-month stay mechanics under the Hatch-Waxman Act. The stay is triggered per ANDA filer upon receipt of Paragraph IV certification notice and runs from that date regardless of procedural consolidation. Each generic filer’s stay expiry date must be independently calculated from the date of Aurinia’s original patent infringement suit against that specific filer.
PatSnap Eureka searches patents and litigation data to answer instantly.